(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose ...

Explore our betting preview for the Utah Utes and Arizona State Sun Devils football game, in their first matchup as Big 12 ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that phase II clinical study results of ...

Friday, Oct. 11 Glass Pumpkin Patch: 10 a.m. to 5 p.m. Friday through Sunday, Oct. 11-13, at Morton Arboretum, 4100 Route 53, ...

The global asthma treatment market size was valued at USD 27.51 billion in 2023 and is expected to reach around USD 35.93 billion by 2034. It is growing at a CAGR of 2.42% from 2024 and 2034. The ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD ...

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader ...

Beyeonics Vision a leading innovator in digital visualization technology for Ophthalmology, proudly announces the launch of Beyeonics One, now featuring cutting-edge invisible light, based on infrared ...

This useful study reports that the exogenous expression of the microRNA miR-195 can partially compensate in early B cell development for the loss of EBF1, one of the key transcription factors in B ...

Two cars collided, injuring 5 total occupants, at the intersection of Route 23 and Perry Road after a grey Toyota Prius ran a ...

Research on the role that genes play in psoriasis has led to targeted therapies to reduce symptoms and slow disease ...